Welcome to our dedicated page for HEMAB THERAPEUTICS HOLDINGS SEC filings (Ticker: COAG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HEMAB THERAPEUTICS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HEMAB THERAPEUTICS HOLDINGS's regulatory disclosures and financial reporting.
Hemab Therapeutics Holdings, Inc. reported that funds managed by RA Capital increased their indirect stake through a mix of open‑market purchases and preferred stock conversions. Over May 4–6, 2026, the funds bought 2,840,429 shares of common stock at prices including $18.00, $24.59, $25.00, $23.77 and $24.83 per share. In connection with the issuer’s initial public offering, all Series A, B and C preferred shares automatically converted to common stock on a 22‑for‑1 basis for no additional consideration. Following these transactions, indirect holdings reported in one line reached 6,314,525 shares of common stock.
Hemab Therapeutics Holdings, Inc. reported that Chief Medical Officer Catherine Madigan received new equity awards. She was granted 145,134 warrants to buy common stock at $6.00 per share, expiring on January 28, 2036. The shares underlying this warrant vest over four years, with 25% vesting on January 1, 2027 and the remainder in equal monthly installments.
Madigan was also granted a stock option for 49,016 shares of common stock at an exercise price of $18.00 per share, expiring on April 29, 2036. These option shares vest in equal monthly installments over four years from May 1, 2026 through May 1, 2030. Both awards are structured as long-term compensation rather than open-market purchases or sales.
Hemab Therapeutics Holdings, Inc. completed its initial public offering of 19,262,500 shares of common stock, including the full underwriter overallotment, at $18.00 per share, generating $346.7 million in gross proceeds before fees.
In connection with the IPO, the company filed a Restated Certificate of Incorporation increasing authorized common stock to 400,000,000 shares, authorizing 5,000,000 shares of undesignated preferred stock, and establishing a classified board with directors removable only for cause by a 75% supermajority vote. The company also adopted amended and restated bylaws that remove stockholder action by written consent, restrict stockholder ability to call special meetings, and add detailed procedures for stockholder proposals and director nominations, along with Delaware and federal exclusive forum provisions.
Hemab Therapeutics Holdings, Inc. is conducting an initial public offering of $301,500,000 by selling 16,750,000 shares of common stock at $18.00 per share. The underwriters have a 30‑day option to purchase up to an additional 2,512,500 shares. Proceeds, before expenses, to the company are stated as $280,395,000. The company expects delivery of shares on or about May 4, 2026 and its common stock is approved to list on the Nasdaq Global Select Market under the symbol COAG.
Following this offering, the prospectus states 27,442,910 shares outstanding as of March 31, 2026 (pro forma basis, reflecting conversions). The prospectus describes Hemab as a clinical‑stage biotechnology company advancing lead programs sutacimig (HMB‑001) and HMB‑002, and discloses cash and marketable securities and use of proceeds detail in the applicable section.
Novo Holdings A/S, a more than 10% owner of Hemab Therapeutics Holdings, Inc., filed an initial Form 3 to report its existing preferred stock holdings. The filing lists Series Seed, Series A, Series B and Series C Preferred Stock, each convertible into specified numbers of Common Stock.
According to the disclosure, each share of these preferred series will automatically convert into Common Stock on a 22-for-1 basis immediately prior to the closing of Hemab’s initial public offering for no additional consideration and with no expiration date. The reported positions represent pre‑IPO economic exposure rather than new market transactions.
Hemab Therapeutics Holdings, Inc. insiders associated with RA Capital filed an initial ownership report showing indirect holdings of Series A, B and C Preferred Stock. These preferred shares are each convertible into Common Stock on a 22-for-1 basis immediately prior to the closing of the company’s initial public offering for no additional consideration.
The filing lists indirect positions held by RA Capital Healthcare Fund LP and RA Capital Nexus Funds II and IV, including Series A Preferred Stock convertible into 609,840 and 1,422,960 underlying Common Stock shares, Series B Preferred Stock convertible into 399,212 and 931,502 underlying shares, and Series C Preferred Stock convertible into 221,188 and 1,253,384 underlying shares. RA Capital Management and related parties disclaim beneficial ownership except to the extent of their pecuniary interest.
Hemab Therapeutics Holdings, Inc. filed an insider ownership report identifying Laura Tadvalkar as a director. The Form 3 data show no buy, sell, or other stock transactions, indicating this filing simply establishes her status as a reporting person for the company’s shares.
Hemab Therapeutics Holdings, Inc. director and officer Benny Sorensen filed an initial ownership report listing several warrant positions on the company’s common stock. These include warrants exercisable at $6.00 for 980,782 underlying shares expiring on January 28, 2036 and warrants at $7.07 for 405,658 shares expiring on August 13, 2033.
Additional holdings are warrants at an exercise price of $2.16 for 251,922 underlying shares expiring on March 20, 2032 and warrants at $6.08 for 76,824 shares expiring on February 1, 2031. Footnotes state one grant from 2021 and one from 2022 are fully vested, while grants from 2023 and 2026 vest over four years with 25% cliff vesting and the remainder in equal monthly installments.